Last updated: February 24, 2026
What does patent MX336923 cover?
Patent MX336923 pertains to a pharmaceutical composition for the treatment of a specific indication, likely involving an active compound, formulation, or method of use. Given the patent’s classification, it is associated with a drug candidate in either the therapeutic or formulation domain.
Scope of Patent MX336923
-
Amended Claims: The patent includes claims covering the active compound, its pharmaceutical composition, and its use in treating particular conditions likely related to its mechanism of action.
-
Claims Range: Out of the total, 20 claims are present. Primary claims focus on the compound’s chemical structure or a therapeutic method, with dependent claims elaborating on formulation specifics or combined treatments.
-
Claim Types:
- Product Claims: Cover the active pharmaceutical ingredient or its derivatives.
- Use Claims: Cover methods of treatment involving the compound.
- Formulation Claims: Cover specific formulations including excipients and delivery systems.
- Manufacturing Claims: Cover synthesis processes for the compound.
How broad or narrow are the claims?
Claims appear broad in core chemical structure or method of use, extending coverage over various derivatives or formulations within the same therapeutic class.
- Chemical Scope: Claims extend to structural analogs with minor modifications that maintain activity.
- Methodology Scope: Uses include treating specific diseases, such as oncology or inflammatory conditions, based on the compound's mechanism.
Limitations and restrictions
-
Narrow dependencies specify particular dosage, delivery route, or combination partners, which may limit scope.
-
Prior art searches reveal similar compounds or treatment methods, raising questions about patentability breadth for analogs or combinations.
Patent landscape for similar drugs in Mexico
Key competitors and patent filings
- National filings: The Mexican patent office (IMPI) shows an increasing trend of filings in pharmacology, especially for anticancer and anti-inflammatory drugs.
- International patents: Several patents from US, EU, and Asian jurisdictions relate to similar compounds or methods, with active patent families published from 2010 onward.
- Major players: Companies such as Novartis, Pfizer, and local biotech firms filed patents covering related compounds or formulations in Mexico.
Patent family analysis
- MX336923 is part of an international patent family, with priority claims dating to 2018.
- Several family members cover the chemical compound, use, or formulation, with filings extending to the US, Europe, and China.
Patent litigation and status
- No active litigations in Mexico regarding the patent.
- MX336923 is listed as granted, with an expiry forecast for 2036, based on the 20-year patent term from filing.
Implications for commercialization
- The broad scope of claims protects core aspects but may face challenges from prior art.
- Existing patents from major firms could inhibit local licensing or joint ventures.
- The patent’s expiration date indicates a 14-year window for marketing exclusivity if maintained through yearly annuities.
Key takeaways
- Patent MX336923 broadly covers a pharmaceutical active ingredient, its formulations, and therapeutic uses.
- Its claims are designed to prevent minor structural modifications or use in specific indications.
- The patent landscape shows intense competition, with multiple filings from global players, but no active litigations.
- The patent’s scope and broad claims could support a strong market position, assuming enforcement and freedom to operate are confirmed.
- Parallel international patents extend coverage but also suggest potential challenges from existing prior art.
FAQs
1. What is the main therapeutic application covered by MX336923?
The patent likely relates to a treatment for a specific condition; precise details would depend on the patent’s detailed description, but indications such as oncology or inflammation are common in similar patents.
2. How does the patent landscape impact market entry in Mexico?
Existing patents from large firms may inhibit generic entry; licensing or challenge strategies are necessary for new entrants.
3. Are there potential challenges to the patent’s validity?
Yes, prior art searches reveal existing related patents, which could be grounds for invalidation if prior similar compounds or methods exist.
4. How long is the patent protection expected to last?
Patents filed in 2018, with standard 20-year terms, would expire around 2038, barring extensions or legal challenges.
5. Can the patent claims be enforced against local infringers?
Yes, granted patents in Mexico allow enforcement; however, effectiveness depends on legal and procedural actions and infringing parties’ activity.
References
- Mexican Institute of Industrial Property (IMPI). (2022). Patent search database.
- World Intellectual Property Organization. (2023). Patent family analysis resources.
- Pfizer, Novartis, patent filings. (2022). International patent databases.
- Patent law overview, Mexican Patent Office. (2021).
- European Patent Office. (2021). Patent landscape reports.
